The Journal of antimicrobial chemotherapy. 2017 Oct 1;72(10):2958-2960. doi: 10.1093/jac/dkx235 Q23.62025
Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters
多替拉韦搭配阿巴卡韦/拉米夫定对青少年有效，但疗效和体重有关 翻译改进
作者单位 +展开
作者单位
DOI: 10.1093/jac/dkx235 PMID: 29091219
摘要 中英对照阅读
相关内容
-
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine
奥比塔斯维-帕利他韦-利托那韦联合达萨布韦与治疗艾滋病的抗逆转录病毒药物多替拉韦或阿巴卡韦和拉米夫定之间相互作用的研究
Amit Khatri et al.
Antimicrobial agents and chemotherapy. 2016 Sep 23;60(10):6244-51.
-
Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food
多替拉韦、阿巴卡韦和拉米夫定复方制剂的生物等效性及其受食物影响的情况
Stephen Weller et al.
Journal of acquired immune deficiency syndromes (1999). 2014 Aug 1;66(4):393-8.
-
Dolutegravir, abacavir and lamivudine as HIV therapy
多替拉韦、阿巴卡韦和拉米夫定作为治疗艾滋病的药物
Jose Vicente Fernandez-Montero et al.
Expert opinion on pharmacotherapy. 2014 May;15(7):1051-7.
-
Dolutegravir / Abacavir / Lamivudine -- Benefit Assessment According to §35a Social Code Book V [Internet]
多替拉韦/阿巴卡韦/拉米夫定---《第五卷社会法典》第35a节规定的效益评估[网络版]
Institute for Quality and Efficiency in Health Care
.
-
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study
拉伏替尼/阿巴卡韦/拉米夫定与当前疗法在病毒抑制患者中的疗效比较（STRIIVING研究）：一项为期48周的随机、非劣效性、开放标签III期试验
Benoît Trottier et al.
Antiviral therapy. 2017;22(4):295-305.
-
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
一项在先前未接受过治疗的感染HIV-1女性中比较多替拉韦、阿巴卡韦和拉米夫定与阿扎那韦/利托那韦增强剂联合恩曲他滨和富马酸替诺福韦二吡呋酯疗效的随机开放性非劣效性3b期研究（ARIA）：第48周结果
Catherine Orrell et al.
The lancet. HIV. 2017 Dec;4(12):e536-e546.
-
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)
从阿巴卡韦/拉米夫定+奈韦拉平转为阿巴卡韦/拉米夫定/多替拉韦治疗HIV-1感染学病毒学抑制成人：SWAD研究
C Allavena et al.
Medecine et maladies infectieuses. 2019 Oct;49(7):505-510.
-
Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy
多替拉韦/阿巴卡韦/拉米夫定在HIV-HCV共感染患者中的临床应用经验-安全性与疗效评估研究
Tamara M Johnson et al.
HIV clinical trials. 2016 Nov;17(6):242-245.
